{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:53:07Z","timestamp":1789656787377,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01251-7","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T07:08:00Z","timestamp":1742022480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Superior preclinical efficacy of co-treatment with BRG1\/BRM and FLT3 inhibitor against AML cells with FLT3 mutations"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7343-6214","authenticated-orcid":false,"given":"Warren","family":"Fiskus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-6009","authenticated-orcid":false,"given":"Christopher P.","family":"Mill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Piel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murphy","family":"Hentemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Birdwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaberi","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-3522","authenticated-orcid":false,"given":"Hanxi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antrix","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Malovannaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan M.","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-9659","authenticated-orcid":false,"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6017-2264","authenticated-orcid":false,"given":"Danielle","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8433-3360","authenticated-orcid":false,"given":"Patrick K.","family":"Reville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren B.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5209-5126","authenticated-orcid":false,"given":"Kapil N.","family":"Bhalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"1251_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1101\/sqb.2016.81.031021","volume":"81","author":"JL Pulice","year":"2016","unstructured":"Pulice JL, Kadoch C. Composition and function of Mammalian SWI\/SNF chromatin remodeling complexes in human disease. Cold Spring Harb Symp Quant Biol. 2016;81:53\u201360.","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"1251_CR2","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2018.09.032","volume":"175","author":"N Mashtalir","year":"2018","unstructured":"Mashtalir N, D\u2019Avino AR, Michel BC, Luo J, Pan J, Otto JE, et al. Modular organization and assembly of SWI\/SNF family chromatin remodeling complexes. Cell. 2018;175:1272\u201388.e20.","journal-title":"Cell"},{"key":"1251_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.molcel.2023.03.013","volume":"83","author":"JE Otto","year":"2023","unstructured":"Otto JE, Ursu O, Wu AP, Winter EB, Cuoco MS, Ma S, et al. Structural and functional properties of mSWI\/SNF chromatin remodeling complexes revealed through single-cell perturbation screens. Mol Cell. 2023;83:1350\u201367.e7.","journal-title":"Mol Cell"},{"key":"1251_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108395","volume":"33","author":"J Wu","year":"2020","unstructured":"Wu J, Krchma K, Lee HJ, Prabhakar S, Wang X, Zhao H, et al. Requisite chromatin remodeling for myeloid and erythroid lineage differentiation from erythromyeloid progenitors. Cell Rep. 2020;33:108395.","journal-title":"Cell Rep."},{"key":"1251_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.tig.2020.07.011","volume":"36","author":"RC Centore","year":"2020","unstructured":"Centore RC, Sandoval GJ, Soares LMM, Kadoch C, Chan HM. Mammalian SWI\/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet. 2020;36:936\u201350.","journal-title":"Trends Genet"},{"key":"1251_CR6","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2013-02-483495","volume":"123","author":"M Buscarlet","year":"2014","unstructured":"Buscarlet M, Krasteva V, Ho L, Simon C, H\u00e9bert J, Wilhelm B, et al. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood. 2014;123:1720\u20138.","journal-title":"Blood"},{"key":"1251_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1541-7786.MCR-21-0390","volume":"20","author":"F Rago","year":"2022","unstructured":"Rago F, Rodrigues LU, Bonney M, Sprouffske K, Kurth E, Elliott G, et al. Exquisite sensitivity to dual BRG1\/BRM ATPase inhibitors reveals broad SWI\/SNF dependencies in acute myeloid leukemia. Mol Cancer Res. 2022;20:361\u201372.","journal-title":"Mol Cancer Res"},{"key":"1251_CR8","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1073\/pnas.1316793111","volume":"111","author":"GR Hoffman","year":"2014","unstructured":"Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, et al. Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci USA. 2014;111:3128\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1251_CR9","doi-asserted-by":"publisher","first-page":"10155","DOI":"10.1021\/acs.jmedchem.8b01318","volume":"61","author":"JPN Papillon","year":"2018","unstructured":"Papillon JPN, Nakajima K, Adair CD, Hempel J, Jouk AO, Karki RG, et al. Discovery of orally active inhibitors of Brahma homolog (BRM)\/SMARCA2 ATPase activity for the treatment of Brahma related gene 1 (BRG1)\/SMARCA4-mutant cancers. J Med Chem. 2018;61:10155\u201372.","journal-title":"J Med Chem"},{"key":"1251_CR10","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","volume":"41","author":"FJ de Miguel","year":"2023","unstructured":"de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, et al. Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer Cell. 2023;41:1516\u201334.e9.","journal-title":"Cancer Cell"},{"key":"1251_CR11","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/blood.2023022832","volume":"143","author":"W Fiskus","year":"2024","unstructured":"Fiskus W, Piel J, Collins M, Hentemann M, Cuglievan B, Mill CP, et al. BRG1\/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood. 2024;143:2059\u201372.","journal-title":"Blood"},{"key":"1251_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"1251_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12185-022-03374-0","volume":"116","author":"Y Arai","year":"2022","unstructured":"Arai Y, Chi S, Minami Y, Yanada M. FLT3-targeted treatment for acute myeloid leukemia. Int J Hematol. 2022;116:351\u201363.","journal-title":"Int J Hematol"},{"key":"1251_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bjh.19519","volume":"205","author":"WY Jen","year":"2024","unstructured":"Jen WY, Kantarjian H, Kadia TM, DiNardo CD, Issa GC, Short NJ, et al. Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease. Br J Haematol. 2024;205:30\u201347.","journal-title":"Br J Haematol"},{"key":"1251_CR15","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/bloodadvances.2019000174","volume":"4","author":"M Levis","year":"2020","unstructured":"Levis M, Perl AE. Gilteritinib: potent targeting of FLT3 mutations in AML. Blood Adv. 2020;4:1178\u201391.","journal-title":"Blood Adv"},{"key":"1251_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","volume":"13","author":"MT Gebru","year":"2020","unstructured":"Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol. 2020;13:155.","journal-title":"J Hematol Oncol"},{"key":"1251_CR17","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739\u201343.","journal-title":"Nucleic Acids Res"},{"key":"1251_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J"},{"key":"1251_CR19","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"1251_CR20","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013W102.","journal-title":"Nucleic Acids Res"},{"key":"1251_CR21","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364.e9.","journal-title":"Cancer Cell"},{"key":"1251_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170:564\u201376.e16.","journal-title":"Cell"},{"key":"1251_CR23","doi-asserted-by":"publisher","unstructured":"Small D. FLT3 mutations: biology and treatment. Hematology Am Soc Hematol Educ Program. 2006:178\u2013184. https:\/\/doi.org\/10.1182\/asheducation-2006.1.178.","DOI":"10.1182\/asheducation-2006.1.178"},{"key":"1251_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/leu.2017.257","volume":"32","author":"K Reiter","year":"2018","unstructured":"Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, et al. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia. 2018;32:313\u201322.","journal-title":"Leukemia"},{"key":"1251_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01103-w","volume":"14","author":"Y Yao","year":"2024","unstructured":"Yao Y, Zhou Y, Zhuo N, Xie W, Meng H, Lou Y, et al. Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia. Blood Cancer J. 2024;14:118.","journal-title":"Blood Cancer J"},{"key":"1251_CR26","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aax3649","volume":"365","author":"S Boettcher","year":"2019","unstructured":"Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, et al. A dominant negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science. 2019;365:599\u2013604.","journal-title":"Science"},{"key":"1251_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood-2006-05-024018","volume":"110","author":"C Choudhary","year":"2007","unstructured":"Choudhary C, Brandts C, Schwable J, Tickenbrock L, Sargin B, Ueker A, et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood. 2007;110:370\u20134.","journal-title":"Blood"},{"key":"1251_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/leu.2009.189","volume":"24","author":"M Jasek","year":"2010","unstructured":"Jasek M, Gondek LP, Bejanyan N, Tiu R, Huh J, Theil KS, et al. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia. 2010;24:216\u20139.","journal-title":"Leukemia"},{"key":"1251_CR29","doi-asserted-by":"publisher","first-page":"10782","DOI":"10.3390\/ijms221910782","volume":"22","author":"B George","year":"2021","unstructured":"George B, Kantarjian H, Baran N, Krocker JD, Rios A. TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation. Int J Mol Sci. 2021;22:10782.","journal-title":"Int J Mol Sci"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01251-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01251-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01251-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T07:08:02Z","timestamp":1742022482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01251-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1251"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01251-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KNB has received research funding from Iterion, Foghorn and Nurix Pharmaceuticals, and he serves as a consultant for Iterion Therapeutics. Jessica Piel, Mike Collins and Murphy Hentemann are employed by Foghorn Therapeutics. All other authors declare they have no conflict of interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}